{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:49:31Z","timestamp":1785577771899,"version":"3.56.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jpba.2021.114348","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:57:44Z","timestamp":1630709864000},"page":"114348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Sensitive quantification of free pazopanib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and assessment of clinical application"],"prefix":"10.1016","volume":"206","author":[{"given":"Asami","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-1711","authenticated-orcid":false,"given":"Ken","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5138-8952","authenticated-orcid":false,"given":"Kazuhiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tatsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.114348_bib1","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jpba.2021.114348_bib2","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.jpba.2021.114348_bib3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","article-title":"Pre-clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor","volume":"15","author":"Hamberg","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jpba.2021.114348_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1254\/fpj.141.37","article-title":"Pharmacological and clinical effects of pazopanib hydrochloride (VOTRIENT\u00ae tablet), an anti-malignant soft tissue tumor drug","volume":"141","author":"Arai","year":"2013","journal-title":"Folia Pharm. Jpn."},{"key":"10.1016\/j.jpba.2021.114348_bib5","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group, Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2021.114348_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000324900","article-title":"Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase","volume":"87","author":"Takahashi","year":"2011","journal-title":"Pharmacology"},{"key":"10.1016\/j.jpba.2021.114348_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jpba.2021.114348_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2015.05.009","article-title":"Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors","volume":"152","author":"Terada","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2021.114348_bib9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clgc.2015.01.007","article-title":"Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma","volume":"13","author":"Noda","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.jpba.2021.114348_bib10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2021.114348_bib11","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jpba.2021.114348_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.jpba.2021.114348_bib13","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1158\/1078-0432.CCR-16-1255","article-title":"Individualized pazopanib dosing: a prospective feasibility study in cancer patients","volume":"23","author":"Verheijen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2021.114348_bib14","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00280-017-3463-x","article-title":"Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization","volume":"80","author":"Verheijen","year":"2017","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.jpba.2021.114348_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clgc.2018.12.001","article-title":"Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma","volume":"17","author":"Noda","year":"2018","journal-title":"Genitourin. Cancer"},{"key":"10.1016\/j.jpba.2021.114348_bib16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/FTD.0000000000000821","article-title":"Development of a high-throughput quantification method for pazopanib using ultra-performance liquid chromatography-tandem mass spectrometry and its clinical application in patients with soft tissue tumors","volume":"43","author":"Shiraiwa","year":"2021","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2021.114348_bib17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40261-015-0334-2","article-title":"Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients","volume":"35","author":"Bergmann","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.jpba.2021.114348_bib18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/clpt.1991.155","article-title":"Relation of systemic exposure to unbound etoposide and hematologic toxicity","volume":"50","author":"Stewart","year":"1991","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2021.114348_bib19","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpba.2018.11.047","article-title":"Development and validation of sensitive and selective quantification of total and free daptomycin in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry","volume":"165","author":"Tanaka","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114348_bib20","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.bbmt.2018.01.040","article-title":"Pharmacokinetic and pharmacodynamic markers of mycophenolic acid associated with effective prophylaxis for acute graft-versus-host disease and neutrophil engraftment in cord blood transplant patients","volume":"24","author":"Yoshimura","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.jpba.2021.114348_bib21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cpt.1810","article-title":"Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients","volume":"108","author":"Kubota","year":"2020","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2021.114348_bib22","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation, 2018. \u3008https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf\u3009. (Accessed 9th May 2021)."},{"key":"10.1016\/j.jpba.2021.114348_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2013.08.013","article-title":"A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry","volume":"937","author":"van Erp","year":"2013","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2021.114348_bib24","doi-asserted-by":"crossref","first-page":"03813","DOI":"10.1016\/j.heliyon.2020.e03813","article-title":"HPLC-MS\/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma","volume":"6","author":"Toh","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.jpba.2021.114348_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10637-015-0304-9","article-title":"Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site","volume":"34","author":"Imbs","year":"2016","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.jpba.2021.114348_bib26","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/jps.23614","article-title":"Plasma protein binding: from discovery to development","volume":"102","author":"Bohnert","year":"2013","journal-title":"J. Pharm. Sci."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521004593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521004593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:14:13Z","timestamp":1760001253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521004593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":26,"alternative-id":["S0731708521004593"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114348","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sensitive quantification of free pazopanib using ultra-high performance liquid chromatography coupled to tandem mass spectrometry and assessment of clinical application","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114348"}}